Federal Register #1:26cv02450

Antitrust Penalties and Compliance Requirements for Edwards Lifesciences and Genesis MedTech

This notice concerns the outcome of an antitrust enforcement action by the U.S. Department of Justice, Antitrust Division, regarding premerger notification violations: - Government buyer: United States Department of Justice, Antitrust Division - OEMs and vendors mentioned: - Edwards Lifesciences Corp. - Genesis MedTech Group Limited - JC Medical, Inc. - JenaValve Technology, Inc. - No products or services are being procured; this is a legal enforcement action, not a procurement opportunity - Key requirements and penalties: - Edwards Lifesciences Corp. must pay a $10 million civil penalty - Genesis MedTech Group Limited must pay a $2 million civil penalty - Edwards must implement an antitrust compliance program, including: - Appointment of an Antitrust Compliance Officer - Distribution of the Final Judgment to relevant personnel - Training and annual certifications - Reporting obligations - Edwards must notify the FTC at least 30 days before acquiring any firm involved in selling or clinical trials for transcatheter aortic valve replacement for aortic regurgitation (TAVRAR) devices in the U.S. - Compliance and notification obligations for Edwards last five years from judgment entry - Genesis' obligations end upon payment of the penalty - Notable: The action centers on the acquisition of JC Medical, Inc. and related investments exceeding HSR Act thresholds, with future compliance focused on TAVRAR device market competition

Description

This notice pertains to the proposed final judgment and competitive impact statement in the matter of the United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited. The United States filed a complaint alleging that Edwards' acquisition of JC Medical, Inc. from Genesis violated the Hart-Scott-Rodino Act by failing to comply with premerger notification and waiting requirements. The proposed final judgment requires Edwards to pay a $10 million civil penalty, institute an antitrust compliance program, and provide FTC notice before acquiring firms involved in clinical trials for a specific medical device. Genesis is required to pay a $2 million civil penalty. Public comments are invited within 60 days of the notice date.

View original listing